*NEW EPISODE* - Early Triple Negative Breast Cancer We talk about the two biggest trials in #TNBC trials that have come out this decade, looking at PCR, EFS and OS! Tune in, a great way to spend your weekend :) #BreastCancer #CREATEX #KEYNOTE522 open.spotify.com/episode/2D9IWm…

*NEW EPISODE* - Metastatic HR +ve Breast Cancer CDK4/6 changed the #breastcancer landscape. With more trials underway next generationxt-gen of drugs on the horizon, we revisit where it all started. #oncology #MONARCH3 #PALOMA2 #MONALEESA2 open.spotify.com/episode/7e2HO2…

Inflammatory Breast Cancer is a rare, often undiagnosed subtype of breast cancer. This week, we interview Dr Massimo Cristofinelli, a leader in this field, along with precision oncology, metastatic breast cancer and liquid biopsies from Weill Cornell Medicine Meyer Cancer Center open.spotify.com/episode/6U9rw6…

*NEW EPISODE - BLADDER CANCER* This week, we explore muscle-invasive bladder cancer (MIBC). We compare two important chemotherapy regimens. The second trial utilises immunotherapy (durvalumab) in the perioperative landscape and is the first trial to do so. How will this impact

'Are adjunctive therapies in colon cancer as good as a drug?' Powerful world-first CHALLENGE CO.21 data from #ASCO2025 today showing we can 🚨 now prescribe exercise in addition to standard treatment🚨 Time to rethink cancer $$ ➡️ #ExerciseOncology nejm.org/doi/full/10.10…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Thanks to ASCO and ECO for collaborating with COSA on fresh approach to healthy workplace cultures in contemporary systems

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. ASCO #ASCO25 OncoAlert

Interesting data in the first line, but OS still immature. Questions remain regarding toxicity and longer follow up

Exciting advances in sclc, small but not insignificant! Good to see a focus on these difficult to treats cancers

A mini-thread for all of SOFT/TEXT 15 year update #ASCO25 1/2

#ASCO25 - Plenary Part 2 We cover two mega-trials today, the first being SERENA-6 and the second being NIVOPOSTOP, both landmark trials with unique designs and a taste of the future of oncology and precision medicine. #breastcancer #cancer ASCO BCNA #HNSCC

#ASCO25 - #BreastCancer with Dr Adam Brufsky We unpack game-changing insights from ASCO 2025 and discuss #SERENA6, which examines camizestrant plus CDK4/6 inhibitors in HR-positive, ESR1-mutated breast cancer; the #DESTINYBreast09 trial, highlighting trastuzumab deruxtecan in

#ASCO25 - Prostate Cancer with Athony Joshua Today, we’re joined by Professor Anthony Joshua, head of Medical Oncology at St Vincent’s Health Network Sydney, Garvan Institute of Medical Research and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses

#ASCO25 - Lung Caner with Ned McNamee #lungcancer treatment continues to rapidly evolve, and this year was no different. Ned talks about pivotal studies including DELLPHI304 and Checkmate 816 Garvan Institute of Medical Research UNSW Lung Cancer Europe LungCancerFoundation open.spotify.com/episode/1vcJhc…

#ASCO25 - Gynaecological Oncology with Prachi Bhave Today, we have the ultimate oncologist on our show, who explores #gynaeonc to its fullest potential. Trials discussed include: #TRUST, #Rosella, #FIRST & @KeynoteA18 European Journal of Gynaecological Oncology The National Gynae-Oncology Registry pearl lamb open.spotify.com/episode/6WRpe0…